



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	January 27, 2020

CERDELGA® (eliglustat)

LENGTH OF AUTHORIZATION: UP TO ONE YEAR

REVIEW CRITERIA:

- Patient must be ≥ 18 years of age.
- Must have documented (in “health conditions” or medical records) diagnosis of Gaucher Disease Type I.
- Submission of an FDA cleared test to determine the CYP2D6 genotype.

DOSING AND ADMINISTRATION:

Recommended dose is 84mg once daily for poor metabolizers.

Recommended dose is 84mg twice daily for intermediate and extensive metabolizers.